Panel adopts Senate amendments and passes prescription-drug affordability bill with rare-disease guardrails

Madam Chair convened the Insurance and Pharmaceuticals Subcommittee and opened consideration of Senate Bill 357, a prescription drug affordability measure cross-filed as House Bill 424. Lisa, a committee staff member, told members the Senate added three stakeholder-council seats — a representative of the rare-disease community, an oncologist and a patient-advocacy representative — and added reporting requirements and a requirement that the board consider how upper payment limits would affect patients with rare diseases.

Madam Chair and Lisa said the Senate changes were intended to fine-tune board processes and did not change the bill’s intent or core operations. "The amendments really do not change the intent of the bill or the operation of the bill at all," Madam Chair said. Delegate Kaiser asked whether the rare-disease provision was meant to allow the board and the legislature to monitor and, if necessary, adjust next session; Madam Chair confirmed that was the rationale and said it places an "extra burden on the board to be extra diligent around drugs that are for rare diseases."

The committee moved to adopt the Senate amendments and then voted on the bill as amended. With no recorded opposition, Madam Chair declared SB 357 passed. The committee also noted that House Bill 376 would be held for a later subcommittee meeting.

Next steps: the bill was approved by the subcommittee as amended; any subsequent legislative action will follow the normal chamber procedures. The committee did not record individual member votes in the transcript; outcomes were announced as unanimous in the remote session.